PX-866 (CAS 502632-66-8)
QUICK LINKS
PX-866 is a compound used extensively in biochemical research due to its inhibitory activity against a specific class of enzymes. It is particularly useful in studies exploring signal transduction pathways, where it helps in dissecting the role of these enzymes in cellular communication and response mechanisms. PX-866 provides researchers with a tool to investigate the consequences of enzyme inhibition on cell proliferation, survival, and differentiation in various cell types. This compound is also utilized in the study of angiogenesis and its role in the development of new blood vessels. Furthermore, PX-866 is of interest in the field of cancer research, where it is used to understand the molecular underpinnings of tumor growth and metastasis. Researchers may employ this compound to evaluate how the inhibition of specific enzymes affects cancer cell viability and behavior, which can contribute to the identification of potential targets for new research avenues.
PX-866 (CAS 502632-66-8) References
- Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma. | Gwak, HS., et al. 2011. Int J Cancer. 128: 787-96. PMID: 20473884
- A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. | Hong, DS., et al. 2012. Clin Cancer Res. 18: 4173-82. PMID: 22693357
- A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. | Bowles, DW., et al. 2013. Br J Cancer. 109: 1085-92. PMID: 23942080
- A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck. | Bowles, DW., et al. 2014. Invest New Drugs. 32: 1197-203. PMID: 24916771
- A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer. | Levy, B., et al. 2014. J Thorac Oncol. 9: 1031-1035. PMID: 24926548
- A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. | Jimeno, A., et al. 2015. Ann Oncol. 26: 556-61. PMID: 25524478
- A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. | Jimeno, A., et al. 2015. Oral Oncol. 51: 383-8. PMID: 25593016
- Phase II study of PX-866 in recurrent glioblastoma. | Pitz, MW., et al. 2015. Neuro Oncol. 17: 1270-4. PMID: 25605819
- Combinatorial PX-866 and Raloxifene Decrease Rb Phosphorylation, Cyclin E2 Transcription, and Proliferation of MCF-7 Breast Cancer Cells. | Peek, GW. and Tollefsbol, TO. 2016. J Cell Biochem. 117: 1688-96. PMID: 26660119
- Down-regulation of hTERT and Cyclin D1 transcription via PI3K/Akt and TGF-β pathways in MCF-7 Cancer cells with PX-866 and Raloxifene. | Peek, GW. and Tollefsbol, TO. 2016. Exp Cell Res. 344: 95-102. PMID: 27017931
- A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. | Bowles, DW., et al. 2016. Clin Colorectal Cancer. 15: 337-344.e2. PMID: 27118441
- A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. | Yam, C., et al. 2018. Clin Cancer Res. 24: 22-32. PMID: 29051322
- A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. | Hotte, SJ., et al. 2019. Clin Genitourin Cancer. 17: 201-208.e1. PMID: 31056399
- Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells. | Harder, BG., et al. 2019. Mol Med. 25: 49. PMID: 31726966
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PX-866, 1 mg | sc-396764 | 1 mg | $149.00 | |||
PX-866, 5 mg | sc-396764A | 5 mg | $288.00 |